试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-05
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
编号:NCT04260009登记状态:入组前撤回企业 / 申办者:Takeda
药物 / 成分:Brigatinib、Brigatinib AAF
登记的停止原因(原文):Business reason unrelated to product safety
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-04
HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma
编号:NCT02487849登记状态:入组前撤回企业 / 申办者:Krankenhaus Barmherzige Schwestern Linz
药物 / 成分:HIPEC、Carboplatin
登记的停止原因(原文):actually limited personnel ressources
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-04
RA Effect on Cell Surface Molecules in Vivo
编号:NCT03753867登记状态:入组前撤回企业 / 申办者:Ottawa Hospital Research Institute
药物 / 成分:Acitretin
登记的停止原因(原文):The study was withdrawn.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-04
Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics
编号:NCT03862079登记状态:入组前撤回企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Best Practice、Fecal Microbiota Transplantation、Nystatin、Piperacillin-Tazobactam
登记的停止原因(原文):Per PI's request
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-03
Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain
编号:NCT01615627登记状态:入组前撤回企业 / 申办者:Jewish General Hospital
药物 / 成分:HypotonicTreprostinil Solution、Eutonic Treprostinil Solution
登记的停止原因(原文):No enrollment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-03
Imaging With [11C]Martinostat in Breast Cancer
编号:NCT03721211登记状态:入组前撤回企业 / 申办者:Christine Elizabeth Edmonds
药物 / 成分:[11C]Martinostat、MR-PET scanner
登记的停止原因(原文):Principal investigator left the study institution.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-03
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
编号:NCT04020653登记状态:入组前撤回企业 / 申办者:Neopharma Japan Co., Ltd.
药物 / 成分:5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD、Sodium ferrous citrate (SFC) 472 mg QD、Artemisinin-based combination (ACT)、Placebo
登记的停止原因(原文):Considering the Thai FDA requirement, changes of Malaria cases in Thailand and EC recommendation, the decision to withdrawal the study was made.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-02
Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery
编号:NCT03446599登记状态:入组前撤回企业 / 申办者:Dartmouth-Hitchcock Medical Center
药物 / 成分:Hydroxocobalamin、Methylene Blue、Normal saline
登记的停止原因(原文):Lack of funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-02-28
Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes
编号:NCT04289948登记状态:入组前撤回企业 / 申办者:University Hospitals of Derby and Burton NHS Foundation Trust
药物 / 成分:Phage
登记的停止原因(原文):Funding issues meant that development of the study was halted.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-02-27
Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer
编号:NCT02811809登记状态:入组前撤回企业 / 申办者:The University of Texas Health Science Center, Houston
药物 / 成分:Apalutamide、IHT
登记的停止原因(原文):Withdrawn due to operational issues. The study was withdrawn early, before enrolling its first participant.
查看官方原始记录 ↗